Please use this identifier to cite or link to this item: http://ir.library.ui.edu.ng/handle/123456789/2644
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTaiwo, B.-
dc.contributor.authorChaplin, B.-
dc.contributor.authorPenugonda, S.-
dc.contributor.authorMeloni, S.-
dc.contributor.authorAkamu, S-
dc.contributor.authorGashau, W.-
dc.contributor.authorIdoko, J.-
dc.contributor.authorAdewole, I.-
dc.contributor.authorMurphy, R.-
dc.contributor.authorKanki, P-
dc.date.accessioned2018-10-16T12:45:06Z-
dc.date.available2018-10-16T12:45:06Z-
dc.date.issued2010-
dc.identifier.otherCurrent HIVResearch 8, pp.194-198-
dc.identifier.urihttp://ir.library.ui.edu.ng/handle/123456789/2644-
dc.description.abstract"OBJECTIVE:The primary objective of this study was to estimate etravirine activity in a cohort of patients infected with non-B subtype HIV-1 and failing nevirapine-based therapy. MATERIALS AND METHODS:Genotypic resistance testing was performed if viral load was >OR= 1,000 copies/ml after receiving at least six months of therapy. Suboptimal response to etravirine was predicted by a score >OR= 2.5 on the Tibotec weighting schema, >OR= 4 in the Monogram schema, or classification as high to low-level resistant by a modification of the Stanford HIVdb algorithm (Version 5.1.2). Bivariate and multivariate analyses were conducted to determine the risk factors for suboptimal etravirine activity. RESULTS:The patients (n=91) were receiving nevirapine and lamivudine plus stavudine (57.1%) or zidovudine (42.9%). Median duration of nevirapine exposure was 53 weeks (IQR 46-101 weeks). The most common etravirine resistance associated mutations were Y181C (42.9%), G190A (25.3%), H221Y (19.8%), A98G (18.7%), K101E (16.5%), and V90I (12.1%). Suboptimal etravirine activity was predicted in 47.3 to 56.0%. There were disparities in mutations listed in Tibotec versus Monogram Schemas. Predicted suboptimal activity was not associated with nucleoside reverse transcriptase inhibitor (NRTI) used, gender, pretreatment or current CD4 cell count or viral load, subtype or NRTI mutations. CONCLUSION:Etravirine has compromised activity in approximately half of the patients failing nevirapine-based first-line treatment in this cohort, which supports guidelines that caution against using it with NRTIs alone in such patients. "en_US
dc.language.isoenen_US
dc.subjectetravirineen_US
dc.subjectnon-B subtypeen_US
dc.subjectresistanceen_US
dc.subjectresource limited settingen_US
dc.subjectsecond lineen_US
dc.titleSuboptimal entravirine activity is common during failure of nevirapine based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1en_US
dc.typeArticleen_US
Appears in Collections:scholarly works

Files in This Item:
File Description SizeFormat 
[6]art_suboptimal_babafemi_etal_2010.pdf8.5 MBAdobe PDFView/Open


Items in UISpace are protected by copyright, with all rights reserved, unless otherwise indicated.